Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2025 10:46 ET | Source: MISTR

Dua Lipa, Drag Icons, Diplo and Celebrities Headline MISTR’s National PrEP Day Kickoff

West Hollywood, Ca, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Last night, MISTR lit up The Abbey in West Hollywood to launch the inaugural National PrEP Day with a star-powered Blue Carpet Countdown event....
September 17, 2025 07:15 ET | Source: Arch Biopartners

Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly...
July 30, 2025 04:30 ET | Source: Custom Market Insights

[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, July 30, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lenacapavir Injection Market Size, Trends and Insights By Indication (HIV...
July 17, 2025 13:00 ET | Source: Spherix Global Insights

GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of...
May 09, 2025 07:30 ET | Source: MISTR

Lexi Love Rolls into Action with MISTR to Serve Sexual Health Realness

Miami, Florida, May 09, 2025 (GLOBE NEWSWIRE) -- MISTR, the nation’s largest LGBTQ+ telehealth platform for sexual health, just dropped its latest campaign starring none other than Lexi Love — and...
August 29, 2024 14:14 ET | Source: Spherix Global Insights

Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi

EXTON, PA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of...
March 28, 2024 07:00 ET | Source: Xilio Therapeutics, Inc.; Gilead Sciences, Inc.

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

-- Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers -- FOSTER CITY, Calif....
January 10, 2024 07:26 ET | Source: Arch Biopartners

Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from...
December 21, 2023 07:01 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding...
October 18, 2023 07:01 ET | Source: HOOKIPA Pharma Inc.

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical settingA Gilead-led Phase 1 clinical trial to...